[Action of Soviet chemical preparations, reaferon and inducers on the reproduction of HTLV-III retrovirus] NLM AIDSLINE Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Action of Soviet chemical preparations, reaferon and inducers on the reproduction of HTLV-III retrovirus]

Vopr Virusol. 1987 Sep-Oct;32(5):561-5. Unique Identifier : AIDSLINE MED/88128659
Barinskii IF; Gribencha SV; Nesterchuk SL; Zhdanov VM

Abstract: The effect of some Soviet chemical drugs (ribamydil, sodium phosphonoformate, acycloguanosine) as well as reaferon (genetic engineering alpha-interferon) and interferon inducers (lafarine, ridastine, rifastine, ENKAD) on HIV retrovirus reproduction was studied in cultures of continuous lymphoid cells H9 and a line of H9/IIIB cells persistently infected with HIV virus. The presence of viral antigen in the cells was determined by quantitative indirect immunofluorescence assays using a working dilution of 1:20 of a serum from an AIDS patient as the immune serum. The above studies showed that 3 drugs: ribamydil (50 micrograms/ml), phosphonoformate (120 micrograms/ml) and recombinant interferon (1000 IU/ml) were capable of statistically significant inhibition of retrovirus replication in continuous cultures of T-lymphocytes.
Keywords: Antiviral Agents/*PHARMACOLOGY Comparative Study Depression, Chemical Dose-Response Relationship, Drug English Abstract HIV/*DRUG EFFECTS/PHYSIOLOGY Interferon Inducers/*PHARMACOLOGY Interferon Type I/*PHARMACOLOGY Recombinant Proteins/PHARMACOLOGY Time Factors Virus Cultivation Virus Replication/*DRUG EFFECTS JOURNAL ARTICLE

KWDantiviralagents/KWDpharmacologycomparativestudydepression,chemicaldose-responserelationship,drugenglishabstracthiv/KWDdrugeffects/physiologyinterferoninducers/KWDpharmacologyinterferontypei/KWDpharmacologyrecombinantproteins/pharmacologytimefactorsviruscultivationvirusreplication/KWDdrugeffectsjournalarticle
880530
M8850411

Copyright © 1988 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .